Docetaxel and Flavopiridol in Treating Patients With Refractory Metastatic Pancreatic Cancer

Inclusion Criteria

• Histologically or cytologically confirmed adenocarcinoma of the pancreas
• Evidence of metastatic disease
• Measurable disease, defined as ≥ 1 lesion that can be accurately measured in ≥ 1 dimension (longest diameter to be recorded) as ≥ 20mm with conventional techniques or as ≥ 10 mm with spiral CT scan
• The primary site is not a measurable lesion
• Documented progression with measurable metastatic disease including any 1 of the following criteria:
• Receiving adjuvant therapy for resected disease
• Receiving therapy for locally advanced disease
• Within 3 months of completing adjuvant therapy or therapy for locally advanced disease
• On 1 prior regimen in the metastatic setting
• No documented brain metastases
• Karnofsky performance status (PS) 80-100% OR ECOG PS 0-1
• WBC ≥ 2,500/mm³
• Absolute neutrophil count ≥ 1,500/mm³
• Platelet count ≥ 100,000/mm³
• Bilirubin ≤ 1.5 times upper limit of normal (ULN)
• AST and ALT grade 1
• No immune deficiency
• Atl east 2 weeks since prior chemotherapy (6 weeks for nitrosoureas, carmustine, or mitomycin C) and recovered
• At least 2 weeks since prior targeted therapy (e.g., antiangiogenic therapy [e.g., bevacizumab] or epidermal growth factor receptor [EGFR] tyrosine kinase inhibitor [e.g., erlotinib hydrochloride]) and recovered
• At least 4 weeks since prior radiation therapy
• No prior docetaxel or flavopiridol
• No other concurrent chemotherapy or investigational agents
• No other concurrent anticancer agents or therapies
• No concurrent commonly used vitamins, antioxidants, orherbal preparations or supplements
• Single-tablet multivitamin allowed
• No concurrent combination antiretroviral therapy for HIV-positive patients